Analysts Have Made A Financial Statement On Exact Sciences Corporation’s (NASDAQ:EXAS) First-Quarter Report
How did your country report this? Share your view in the comments.
Introduction:
The news topic “Analysts Have Made A Financial Statement On Exact Sciences Corporation’s (NASDAQ:EXAS) First-Quarter Report” has drawn international attention, with various media outlets providing diverse insights, historical context, political stances, and on-the-ground developments. Below is a curated overview of how different countries and media organizations have covered this topic recently.
Quick Summary:
- Exact Sciences Corporation’s (NASDAQ:EXAS) stock price is up 13% to US$51.55 following its latest quarterly results. Revenues of US$707m did beat expectations by 2.6%, but statutory losses grew 42% toUS$0.54 per share. Earnings are an important time for investors to track a company’s performance, look at what the analysts are forecasting for next year, and see if there’s been a change in sentiment towards the company. With this in mind, we’ve gathered the latest statutory forecasts to see what theAnalysts are expecting for the company next year. See what we found for Exact Sciences in our free report. The analysts are now forecasting revenues of US $3.09b in 2025. This would be a decent 9.4% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 91%.
- Exact Sciences (NASDAQ:EXAS) reported its first quarter results on May 3rd 2025. Revenues exceeded analyst estimates by 2.6%, but earnings per share (EPS) missed by 42%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. The company’s shares are up 13% from a week ago. See the full list of 21 US stocks forecast to pay a dividend yield of over 6% next year to see the rest of the list. We’ve done some analysis and you can see our take on Exact Sciences’ balance sheet. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
- Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript May 1, 2025. Reported EPS is $-0.21, expectations were $- 0.37. Kevin Conroy, Chairman and CEO, and Aaron Bloomer, Chief Financial Officer, on the call today. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. [Operator Instructions] I would now like to turn the conference over to Derek Leckow, Vice President Investor Relations. Please go ahead, sir.Derek Lecklow: Thanks, operator. Thank you for joining us for Exact Sciences first quarter 2025 conference call. During today’S call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements.
Country-by-Country Breakdown:
Original Coverage
Exact Sciences Corporation’s (NASDAQ:EXAS) stock price is up 13% to US$51.55 following its latest quarterly results. Revenues of US$707m did beat expectations by 2.6%, but statutory losses grew 42% toUS$0.54 per share. Earnings are an important time for investors to track a company’s performance, look at what the analysts are forecasting for next year, and see if there’s been a change in sentiment towards the company. With this in mind, we’ve gathered the latest statutory forecasts to see what theAnalysts are expecting for the company next year. See what we found for Exact Sciences in our free report. The analysts are now forecasting revenues of US $3.09b in 2025. This would be a decent 9.4% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 91%. Read full article
Exact Sciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Exact Sciences (NASDAQ:EXAS) reported its first quarter results on May 3rd 2025. Revenues exceeded analyst estimates by 2.6%, but earnings per share (EPS) missed by 42%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. The company’s shares are up 13% from a week ago. See the full list of 21 US stocks forecast to pay a dividend yield of over 6% next year to see the rest of the list. We’ve done some analysis and you can see our take on Exact Sciences’ balance sheet. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. Read full article
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript May 1, 2025. Reported EPS is $-0.21, expectations were $- 0.37. Kevin Conroy, Chairman and CEO, and Aaron Bloomer, Chief Financial Officer, on the call today. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. [Operator Instructions] I would now like to turn the conference over to Derek Leckow, Vice President Investor Relations. Please go ahead, sir.Derek Lecklow: Thanks, operator. Thank you for joining us for Exact Sciences first quarter 2025 conference call. During today’S call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Read full article
Global Perspectives Summary:
Global media portray this story through varied cultural, economic, and political filters. While some focus on geopolitical ramifications, others highlight local impacts and human stories. Some nations frame the story around diplomatic tensions and international relations, while others examine domestic implications, public sentiment, or humanitarian concerns. This diversity of coverage reflects how national perspectives, media freedom, and journalistic priorities influence what the public learns about global events.
How did your country report this? Share your view in the comments.
Sources:
- Original Article
- Exact Sciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
- Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript
Source: https://finance.yahoo.com/news/analysts-made-financial-statement-exact-135827015.html